Position in ENLV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,310,502
+$726,174 QoQ
Shares Held
158,849
+279.2% QoQ
Ownership
0.908%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#1
of 25 holders
Holding Since
Mar 2021
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ENLV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ARK Investment Management LLC holds $2,096,518,225 across 18 Biotechnology names. ENLV ranks #18 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CRSP |
CRISPR Therapeutics AG
|
9,460,939 | $515,999,613 | |
| 2 | TWST |
Twist Bioscience Corp
|
4,549,803 | $468,083,732 | |
| 3 | BEAM |
Beam Therapeutics Inc.
|
10,234,862 | $351,260,463 | |
| 4 | NTLA |
Intellia Therapeutics, Inc.
|
16,875,684 | $285,536,573 | |
| 5 | RXRX |
Recursion Pharmaceuticals, Inc.
|
41,337,632 | $151,709,109 | |
| 6 | ABSI |
Absci Corp
|
12,925,271 | $149,803,890 | |
| 7 | NRIX |
Nurix Therapeutics, Inc.
|
1,793,196 | $43,502,934 | |
| 8 | PRME |
Prime Medicine, Inc.
|
8,348,746 | $30,806,872 |
All Filings in ENLV
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,310,502 | 2,382,731 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $584,328 | 628,310 | Shares | Sole | 2026-05-12 | |
| 2022-06-30 | $1,496,124 | 331,001 | Shares | Sole | 2022-07-11 | |
| 2022-03-31 | $2,427,977 | 434,343 | Shares | Sole | 2022-04-19 | |
| 2021-12-31 | $2,183,175 | 349,308 | Shares | Sole | 2022-01-28 | |
| 2021-09-30 | $4,523,034 | 457,797 | Shares | Sole | 2021-11-12 | |
| 2021-06-30 | $4,581,782 | 514,807 | Shares | Sole | 2021-08-05 | |
| 2021-03-31 | $5,283,431 | 476,414 | Shares | Sole | 2021-05-13 | |
| No filing history on record for this holder in this stock. | ||||||